DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Information source: Novartis
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Wet Age-Related Macular Degeneration

Intervention: PTK787 (Drug); PTK787 (Drug); Placebo (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Novartis

Official(s) and/or principal investigator(s):
Novartis Customer Information, Study Chair, Affiliation: Novartis

Summary

This study evaluates the tolerability and safety of 3 months treatment with PTK787 tablets given daily. It also explores the efficacy of the compound in patients with wet age-related macular edema. In Cohort 1 verteporfin/PDT is the active control. The protocol was amended to reflect the current standard of care for AMD. As a result, ranibizumab is the active control for Cohort 2.

Clinical Details

Official title: A Randomized, Double-Masked, Multicenter, Phase I/II Study of the Safety of PTK787 Administered to Patients With Predominantly Classic , Minimally Classic or Occult With no Classic Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Safety as assessed by visual acuity measurements, ophthalmic examinations, vital signs, laboratory assessments, and adverse events up to 12 months

Secondary outcome: Change in macular edema from Baseline up to Month 3 Change in best-corrected visual acuity (BCVA) from Baseline up to Month 3 Change in size of fluorescein leakage Baseline up to Month 3

Eligibility

Minimum age: 65 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion criteria

- Male ≥ 65 years old or female ≥ 50 years old, with aged related macular degeneration

- Patients with subfoveal choroidal neovascularization secondary to AMD

Exclusion criteria

- Eye disease that may result in visual loss during the study

- Uncontrolled high blood pressure, despite chronic stable treatment: systolic ≥ 140

mmHg, Diastolic ≥ 90 mmHg

- Chronic therapy with topical, local or systemic corticosteroids.

- Use of other investigational drugs within 30 days

- Pregnant or nursing (lactating) women.

Other protocol-defined inclusion/exclusion criteria may apply

Locations and Contacts

Retina-Vitreous Associates Medical Group, Beverly Hills, California 90211, United States

Porter Adventist Hospital, Eye Lab, Denver, Colorado 80210, United States

USF Eye Institute, Tampa, Florida 33612-4742, United States

Springfield Clinic, LLP, Springfield, Illinois 62701, United States

Wilmer Eye Institute, Baltimore, Maryland 21287, United States

Lahey Clinic Medical Center, Eye institute, Peabody, Massachusetts 01960, United States

Novartis Investigative Site, Parramatta, New South Wales 2150, Australia

Novartis Investigational Site, Sydney, New South Wales 2000, Australia

Novartis Investigative Site, Westmead, New South Wales 2145, Australia

Black Hills Regional Eye Institute, Rapid City, South Dakota 05770, United States

Novartis Investigative Site, East Melbourne, Victoria 3002, Australia

Additional Information

Starting date: September 2005
Last updated: November 12, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017